We previously described Ad-D24RGD as an enhanced-infectivity oncolytic adenovirus that targets tumors with an impaired RB pathway. The common alteration of this pathway in cancer eliminates the interaction of pRB with E2F and releases free E2F to activate E2F-responsive promoters, including the E2F-1 promoter. To improve the selectivity towards RB pathway-defective tumors and reduce the toxicity of Ad-D24RGD we aimed to control E1A-D24 expression under the E2F-1 promoter. A polyA signal was inserted upstream of the E2F-1 promoter to stop transcription initiated at the adenovirus ITR and packaging signal. The human myotonic dystropy locus insulator (DM-1) was also located between the E1a enhancers and the E2F-1 promoter to further insulate the promoter. The Ad-D24RGD derivative containing these insulation sequences expressed less E1a-D24 in normal cells and resulted less toxic while maintaining the potent oncolytic activity of the parental virus. These results demonstrate that the human DM-1 inslulator can function in an adenovirus context to maintain heterologous promoter selectivity. The new oncolytic adenovirus presented here may represent a valuable therapeutic option for a broad range of tumors with a deregulated E2F/pRB pathway.
Introduction
Adenoviruses engineered to replicate only in tumor cells are being evaluated as a new cancer therapy. Adenovirus replication may be regulated at different levels to be tumor selective. In recent years, two major strategies have been developed. Viral genes that become dispensable in tumor cells, such as the genes responsible for activating the cell cycle through binding to p53 or pRb, have been completely or partially deleted. 1, 2 Similarly, some viral genes involved in counteracting antiviral mechanisms of infected cells become dispensable in Ras-activated tumors and its deletion has been used to generate oncolytic vectors. 3 A second strategy aims to control the transcription of adenovirus early gene regions (such as E1A, E1B, E2 or E4) replacing the native viral promoters with cellular promoters that are active in tumor cells, referred as 'tumor-specific' promoters. Several promoters including the a-fetoprotein, 4 the prostate-specific antigen 5 or the tyrosinase 6 have been used to restrict the adenovirus E1A gene expression to treat hepatocarcinoma, prostate carcinomas, or melanomas, respectively. However, tumor heterogeneity makes unlikely that all the cells within a tumor express a specific tumor marker, and this could result in a selective advantage to non-expressing tumor cells.
Systemic delivery of the oncolytic virus is a requisite for a therapeutic option when applied to most types of tumors in an advanced stage. Adenovirus is not a bloodborne virus and few minutes after intravenous injection it is cleared from the bloodstream and accumulated into the liver. 7, 8 Kupffer cells clear most of the virus and limit the amount of virus available for infection of tumors. [8] [9] [10] They contribute to hepatotoxicity with the activation of innate immune responses that involve short-term secretion of inflammatory cytokines triggered by the adenovirus particle. [10] [11] [12] However, hepatotoxicity has been mainly associated to the expression of early virus genes in hepatocytes. 13 This preclinical data along with the information of hepatotoxicity from early clinical trials indicates that the control of early viral proteins in the liver is a crucial step towards the clinical use of adenovirus as therapeutic tool.
The E1A promoter has been substituted by the human E2F-1 promoter to achieve tumor-selective replication of adenovirus. [14] [15] [16] The E2F family of transcription factors plays an essential role in the entry to the S-phase of the cell cycle by regulating the transcription of a diverse set of genes. 17, 18 E2F function is repressed when bound to the retinoblastoma tumor-suppressor protein (pRb). Binding of E2F factors to unphosphorylated pRb blocks E2F-mediated transactivation but also actively represses transcription when this complex binds to a promoter. 19 It is currently accepted that all tumors present changes in the RB pathway that inhibit pRb binding to E2F, which results in an increase in free E2F. 20 The E2F-1 gene itself is transcriptionally activated by free E2F. Oncolytic adenoviruses with E1A under the control of E2F-1 promoter take advantage of this E2F-1 activity in tumor cells and have demonstrated increased tumor selectivity and reduced hepatic toxicity.
The use of selective promoters to control E1A gene expression can be insufficient to ensure targeted gene expression in an adenoviral vector context. It has been described that expression cassettes delivered through adenoviruses suffer promoter interference. 21, 22 Transcriptional read-through from start sites at the ITR or at the packaging signal has been reported. 23, 24 A first approach to circumvent this problem has been the introduction of transcription terminators upstream of the heterologous promoter. 23, 25 In addition, the presence of cis-acting enhancer elements within the adenoviral packaging signal has been identified as another interfering element. 26 In order to block the effect of this enhancer an insulator from the DNAse hypersensitivity region 4 (HS4) of the chicken b-globin gene has been inserted between the enhancer and the heterologous promoter. 27, 28 A comparison of transcriptional terminators versus enhancerblocking sequences such as HS4 revealed that the later are a better option to insulate promoters in adenovirus. 28 The insulation mechanism of HS4 is based on the binding of the zinc-finger protein CTCF that mediates the inhibition of promoter-enhancer interactions. All the enhancer-blocking elements identified in vertebrates bind CTCF. 29 The human myotonic dystrophy (DM) locus on chromosome 19q13.3 contains two binding sites for CTCF and a variable number of CTG repeats that together function as a potent insulator. 30 Although the insulator activity of DM-1 has never been tested in adenovirus, the fact that, like HS4, it works through CTCF, its compact size, and human origin makes it specially attractive for selectively replicating adenoviruses.
In the present study, we describe the introduction of a DM-1 insulator to improve the fidelity of the human tumor-selective E2F-1 promoter in the previously described AdD24RGD vector. 31 We have constructed two new viruses that differ in their sequence between adenoviral packaging signal and the E2F1-promoter region. ICOVIR-1 only includes a poly-A signal from pGL3 plasmid preceding the promoter, whereas ICOVIR-2 also contains the human DM-1 element to insulate the E2F-1 promoter. Both viruses demonstrated higher levels of E1A expression as well as viral production in tumor cell lines than in normal cells without any significant loss of antitumoral efficacy, but the presence of the DM-1 insulator resulted in a better promoter fidelity.
Materials and methods

Cell lines
The Ad5 E1-transformed human embryonic kidney cell line 293, the human lung adenocarcinoma cell line A-549, the human squamous head and neck carcinoma cell lines FaDu and SCC25 and the human melanoma cell lines SKMel-28 and 1.36.1.5 were obtained from the ATCC (Manassas, VA). The human pancreatic carcinoma cell line NP-9 was established in our laboratory from perpetuated xenografts orthotopically implanted in nude mice. 32 Antonio Tugores (Almirall-Prodesfarma, Barcelona, Spain) kindly provided human fibroblasts. Cells were grown in Dulbecco's-modified Eagle's medium containing 5% fetal bovine sera. Human umbilical vein endothelial cell (HUVEC) cells were purchased from Cambrex Bio Science Baltimore Inc. (Baltimore, MD) and cultured in endothelial cell medium. Murine hepatocytes were isolated from male Balb/c mice by a two-step collagenase perfusion method 33 and seeded in collagencoated plates. Similarly, primary cultures of human hepatocytes were obtained from a liver biopsy using a two-step perfusion technique and also seeded on collagencoated plates as previously described. 34 
Plasmids and adenoviruses
The replication-competent Ad-D24RGD adenovirus has been previously described. 31 This virus contains a 24 basepair deletion of the E1A region responsible for pRB protein binding (Ad5 genome nt 923-946) and an RGD sequence inserted in the HI loop of the fiber knob protein to target integrins of the surface of cancer cells as its primary receptor. To generate ICOVIR-1 (Ad-E2F-D24RGD), the human E2F-1 promoter was obtained from normal human peripheral blood mononuclear cells by polymerase chain reaction (PCR) using oligonucleotides that amplify from À218 to þ 51 of E2F-1 sequence. A KpnI-HindIII fragment was cloned into pGL3-plasmid (Promega, South Hampton, UK) to generate pGL3-E2F. pE2F-D24 plasmid was obtained by recombination of pGL3-E2F with a plasmid containing the left 5766 bp of Ad5 genome except deletion of amino acids 122-129 of E1A (pXC1-D24 derivative with a HindIII site as a linker between nt 348 and 522 of Ad5 genome 2 ). pE2F-D24 was recombined with pShuttle 35 to obtain pShuttle-E2F-D24. Resulting plasmid was linearized by PmeI digestion and used for homologous recombination in DH5a cells with pVK503 plasmid (which contains complete Ad5 genome with RGD-modified fiber 36 ) to generate pICOVIR-1. The genome of the new virus was released from plasmid backbone by digestion with PacI and transfected into HEK293 cells to rescue ICOVIR-1. A similar procedure was used to generate ICOVIR-2 (Ad-DM-E2F-D24RGD). The human DM-1 insulator genomic DNA was obtained from normal human peripheral blood mononuclear cells by PCR using oligonucleotides that amplify from nt 13 006 to 13 474 of DM-1 locus sequence (GenBank accession no. L08835). This region contains the CTCF-binding sites and the CTG repeats responsible for the insulator activity of the DM-1 locus. 30 The PCR 
. All D24-containing viruses were amplified in A549 and purified using standard two-step CsCl gradient centrifugation. Wild-type adenovirus (Adwt) (ATCC), AdwtRGD (created by digesting pVK503 with PacI and further transfection in 293 cells) and Ad-GFPRGD (non-replicating GFP-expressing, RGD-modified virus) were propagated in 293 cells.
E1A expression analysis
Cell cultures (B2 Â 10 5 cells) were infected at a multiplicity of infection (MOI) that allowed at least 80% infectivity. Control and infected cells were lysed 20 h postinfection by incubating cells in lysis buffer (400 mM NaCl, 1 mM EDTA, 5 mM NaF, 10% glycerol, 1 mM sodium orthovanadate, 0.5% Nonidet P-40, 100 mg/ml phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin and 10 mg/ml aprotinin in 10 mM Tris-HCl (pH 7.4)) for 1 h at 41C. After centrifugation at 14 000 g, supernatant proteins (25 mg/lane, as determined by Bradford assay, BioRad, CA) were electrophoretically separated on 10% SDS-PAGE and transferred to nitro-cellulose membrane (Schleicher and Schuell, Dassel, Germany). Membrane was blocked with 5% non-fat milk, 0.05% Tween 20, 0.9% NaCl in 50 mM Tris (pH 7.5), and incubated overnight at 41C with a primary polyclonal antibody rabbit antiadenovirus-2 E1A (clone 13 S-5, Santa Cruz Biotechnology Inc., Santa Cruz, CA). The secondary antibody was HRP conjugated anti-rabbit IgG (DAKO A/S, Denmark). Membranes were developed according to the Amersham's Enhanced chemioluminiscent protocol (Amersham, Arlington Heights, IL).
Viral yield analysis by anti-hexon staining method
For viral replication analysis, cells were grown to 80% confluence in 24-well plates and subsequently infected with a MOI that allowed at least 80% infectivity. At 5 days after infection both cells and supernatant were collected and subjected to three cycles of freezing and thawing. Viral yield in cell extracts was determined by an a-hexon staining-based method. Briefly, serial dilutions of cell extracts were used to infect 293 cultures. At 48 h after infection, cultures were fixed with methanol 100% for 10 min at À201C and further incubated with mouse anti-hexon (2Hx-2 hybridoma; ATCC) and Alexa 488-labeled goat anti-mouse (Molecular Probes, Eugene, OR) for 1 h at 371C both. Cell monolayers were cleaned twice with PBS-BSA 1% after each incubation. Positive green cells were counted for each dilution in triplicate under a fluorescent microscope.
Liver toxicity assays
Animals form all studies were cared for and manipulated in accordance with recommendations from the federation of European Laboratory Animal Science Associations for the proper use of laboratory animals. A dose of 2 Â 10 12 viral particles/kg was injected intravenously via tail vein in 6-week-old Balb-C male mice at a dose volume of 10 ml/kg (n ¼ 5). Daily observations for body weight and morbidity were performed. Mice were sacrificed 3 days after infection, and different samples collected. Blood samples were obtained by intracardiac punction. Clinical biochemistry for creatinin and transaminase levels were performed by the Clinical Biochemistry Service of the Veterinary Faculty at the Autonomous University of Barcelona (UAB). Mice livers were collected and portions were fixed in formol (for paraffin embedding and further hematoxylin/eosin staining) or frozen in OCT. E1A-immunodetection was performed by incubating OCT-embedded liver sections with a primary polyclonal antibody antiadenovirus-2 E1A (clone 13 S-5, Santa Cruz Biotechnology) and a Alexa Flour 488-labeled goat antirabbit antibody (Molecular Probes, Eugene, OR). Slides were counterstained with 4 0 ,6-diamino-2-phenylindole and visualized under a fluorescent microscope (Olympus BX51).
In vitro cytotoxicity (cytopathic effect (CPE) assay) For CPE assays, cells were seeded in 0.5% fetal bovine serum and infected 24 h later at doses ranging from 50 000 to 0.001 vp/cell. At day 5 post-infection (A549 and SKMel-28 cells) or day 8 post-infection (NP-9, SCC-25 and 1.36.1.5. cells), plates were stained for total protein content (BCA assay; Pierce, Rockford, IL), and the absorbance was quantified. The amount of viral particles/ cell that produced 50% growth inhibition (IC 50 value) was estimated from dose-response curves by standard nonlinear regression (GraFit; Erithacus Software Ltd, Surrey, UK) using an adapted Hill equation.
Suppression of tumor growth in vivo
Subcutaneous NP-9 tumors were established by injection of 12 Â 10 6 cells into the flanks of 6-to 8-week-old male Balb-C nude mice (n ¼ 8). Once tumors had reached 100-200 mm 3 they were injected with PBS, or 10 9 vp of AdwtRGD, ICOVIR-2 in a volume of 25 ml for 3 consecutive days. Tumor size as well as mice status was determined twice weekly, and tumor volume was calculated according to the equation
, where L and W were length and width of the tumor, respectively. Statistical significance in tumor volume between treatment groups was assessed using the Student's unpaired t-test. 
Results
E1A expression and replication of ICOVIR-1 and ICOVIR-2 is decreased in normal cells
Ad-D24RGD genome contains two modifications with respect to Adwt that have been presented previously. 31 First, Ad-D24RGD has a deletion in the pRB-binding site of E1A that results in a protein unable to bind pRb. Second, Ad-D24RGD has an RGD peptide inserted at the fiber that allows the use of integrins as a primary receptor contrary to the RGD of the penton base that functions only after the fiber has bound the natural primary receptor coxsackie adenovirus receptor (CAR). In order to increase Ad-D24RGD selectivity for RB pathway and reduce its toxicity in normal tissues, we constructed two new Ad-D24RGD-derived mutants that contain the mutated E1a under an insulated tumor-specific promoter. ICOVIR-1 and ICOVIR-2 differ in the region that has been incorporated to insulate the E1A transcription unit from non-selective endogenous viral transcription. In ICOVIR-1 the E1A promoter has been replaced by the region À218 to þ 51 from human E2F-1 promoter preceded by a synthetic polyA signal from pGL3 plasmid. In ICOVIR-2, E2F-1 promoter function has been additionally insulated by means of a 0.7 Kb DNA fragment from the myotonic dystrophy locus (DM-1) with enhancer-blocking insulator activity. 30 Figure 1 shows a schematic representation of the different vector genomes used in this study.
To determine the dependence of the new mutants on the status of RB pathway, we analyzed the level of expression of viral E1A and viral replication in different murine and human normal cell types, including human endothelial HUVEC cells, human mesenquimal fibroblasts cells and human and murine hepatocytes. A panel of different viruses was included to normalize for infectivity and virus production differences between cell types: Adwt, RGD-modified wild type (AdwtRGD), the parental Ad-D24RGD and a non-replicative adenovirus expressing GFP (Ad-GFP-RGD). Viral E1A protein expression levels were analyzed 20 h post infection by Western blot. As shown in Figure 2a , AdwtRGD-and Ad-D24RGD-infected cells displayed higher expression of E1A than Adwt-infected ones, which is consistent with an enhancement of infectivity associated to the presence of RGD in the fiber knob. Cultures infected with ICOVIR-1 expressed lower levels of E1A than those infected with AdwtRGD or Ad-D24RGD in all normal cells. E1a expression was further reduced in normal cells infected with ICOVIR-2. Interestingly, the levels of E1A were practically undetectable in primary cultures of human and murine hepatocytes after infection with ICOVIR-2 which is especially relevant since liver cells are the primary targets of adenovirus in vivo upon endovenous administration (Figure 2a) .
Analysis of the progeny production after infection with each virus in these normal cell cultures was performed 5 days after infection. More AdwtRGD than Adwt was produced in both endothelial cells and fibroblasts, a result that reflects the superior infectivity mediated by RGD. In contrast, ICOVIR-1 was attenuated in its ability to replicate in human fibroblasts and HUVEC cells when compared to AdwtRGD. ICOVIR-2 was even more defective than ICOVIR-1 (Figure 2b ). Of note, viral yield after infection with Ad-D24RGD was not reduced compared to AdwtRGD in these normal cells consistent with results also obtained in fibroblasts and HUVEC. 37 Introduction of an insulated form of the E2F-1 promoter reduced hepatic toxicity in vivo To evaluate the hepatic toxicity related to early viral protein expression and the capability of the DM-insulated E2F-1 promoter to control it, the two new Ad-D24RGD derivatives, ICOVIR-1 and ICOVIR-2, were systemically administered to immunocompetent Balb/C mice and E1A expression was assessed in liver sections by immunohistochemistry. Animals were weighted daily and selected clinical chemistry parameters were measured at day 3 post-injection, when animals were killed. RGD-modified wild-type adenovirus, Ad-D24RGD and PBS were also injected as controls. All mice received 1 Â 10 12 viral particles/kg by tail-vein injection. As Figure 3a shows, Insulated E2F promoter for RB-dependent oncolysis M Majem et al no significant differences were observed between liver sections of AdwtRGD (a) and Ad-D24RGD-injected mice (b), both showing an intense diffuse E1A expression pattern that correlated with an important degree of tissue degeneration. In contrast, E1A expression in liver sections of ICOVIR-1-injected mice was reduced and the pattern of staining was much less diffuse with a better preserved nuclei morphology (Figure 3a and d) . In addition, in liver sections of ICOVIR-2-injected mice the number of E1A-positive nuclei was significantly lower than in those injected with ICOVIR-1 (Figure 3a and e) . A significant body weight loss was detected only in AdwtRGD and Ad-D24RGD treated animals (8-10% versus day 0). Only the control and ICOVIR-2-treated animals gained weight over the course of the study (Figure 3b ). Plasma levels of creatinine did not differ in any of the treatment groups indicating that there was no evident toxicity in skeletal muscle or kidney. By contrast, both ICOVIR-1 and ICOVIR-2-injected animals displayed significant elevated levels of plasma transaminases (Po0.05 versus PBS-group, Figure 3b) . However, these levels were significantly lower than those of the AdwtRGD or Ad-D24RGD-treated mice (Po0.05 versus AdwtRGD, Figure 3b) .
Potency of ICOVIR-1 and ICOVIR-2 in tumor cell lines
To determine if E1A under an insulated version of the E2F-1 promoter could be efficiently expressed in tumor cell lines without compromising the oncolytic potency of the newly generated mutants, E1A expression 20 h postinfection and virus production 5 days post-infection were tested in a panel of tumor cell lines. Different cell types were selected in order to represent a broad range of tumor types: lung carcinoma (A-549), pancreatic carcinoma (NP-9), head and neck carcinoma (FaDu, SCC25) and melanoma (SK-Mel-28 and 1.36.1.5).
No differences in E1A expression were detected between Ad-D24RGD-and AdwtRGD-infected cultures in all analyzed cell lines as expected because they both contain the wild-type E1A promoter (Figure 4) . Moreover, in three out of six cell lines (NP-9, A549 and 1.36.1.5. cell lines), E1A expression after infection with ICOVIR-1 and ICOVIR-2 was also similar to that observed with AdwtRGD. A slight decrease of expression was noted in FaDu, SCC25 and SKMel-28 ( Figure 4) . Consistent with this E1A expression pattern, viral yield analysis showed no differences between AdwtRGD and Ad-D24RGD as previously reported 31. Data obtained in A-549, SCC25 and NP-9 tumor cell lines showed that production of ICOVIR-1 and ICOVIR-2 was comparable to that of AdwtRGD. In SKMel-28 and FaDu a decrease of ICOVIR-1 and ICOVIR-2 production was detected (Figure 5a) . A correlation between viral production and cytotoxicity of ICOVIR-1 and ICOVIR-2 was observed in the different tumor cell lines (Figure 5b ). Taken together, our data suggest that the oncolytic activity of both mutants is preserved in the presence of the insulated heterologous promoter in most tumor cell lines.
ICOVIR-2 suppresses tumor growth in vivo
Antitumoral effect of ICOVIR-2 was evaluated in vivo using a model of subcutaneously implanted pancreatic tumors in nude mice. Owing to the better selectivity of ICOVIR-2 compared to ICOVIR-1 and their similar antitumoral potency we used only ICOVIR-2 for this in vivo study and included AdwtRGD as a control of maximum potency. NP-9 tumors were intratumorally injected with PBS or 10 9 vp of AdwtRGD or ICOVIR-2 for 3 consecutive days, and tumor growth was monitored. Both ICOVIR-2 and AdwtRGD viruses induced a significant tumor growth inhibition compared to PBSinjected tumors. Of note, ICOVIR-2 had the same antitumoral activity as AdwtRGD. Post-injection tumors (25 days) from ICOVIR-2 and AdwtRGD groups were Insulated E2F promoter for RB-dependent oncolysis M Majem et al 41 and 54% smaller than control tumors, respectively (Po0.05 for both ICOVIR-2 and AdwtRGD with respect to PBS; Figure 6a ). These data indicate that a defective RB pathway allows efficient replication of ICOVIR-2 in vivo. Anti-hexon immunofluorescence was performed on tumor sections of experimental group 25 days posttreatment to obtain evidence that the observed antitumoral effect was associated to the presence of viral replication within the tumor. The presence of positive hexon areas associated with necrosis was detected throughout the tumor in both AdwtRGD and ICOVIR-2-injected tumors (Figure 6b ).
Discussion
Systemic delivery is mandatory for oncolytic virus treatment of most tumor types at an advanced stage. The hepatocyte is the main normal cell that becomes infected with adenovirus upon endovenous injection. Therefore, a tight control of the toxicity and replication of the virus in hepatocytes would improve the therapeutic window of this strategy. The oncolytic adenoviruses presented in this study (ICOVIR-1 and ICOVIR-2) have been designed to improve the selectivity of the previously described Ad-D24RGD. 31 This virus expresses a mutated E1A protein unable to bind pRB (E1A-D24) and has an RGD motif inserted in the viral fiber knob to increase infectivity in cells with low CAR expression. Both, ICOVIR-1 and ICOVIR-2, incorporate the E2F-1 promoter to restrict the expression of E1A-D24 to cells with high levels of free E2F activity. However, they differ in the insulator sequence that has been introduced upstream of the promoter to inhibit the effect of enhancers and transcription start sites located on the adenovirus ITR and packaging signal. While ICOVIR-1 carries a poly-A signal upstream of E2F-1 promoter, ICOVIR-2 also contains the DM-1 element responsible for insulating the human myotonic dystrophy locus. Insulated E2F promoter for RB-dependent oncolysis M Majem et al E2F-1 promoter enhanced the selectivity of Ad-D24RGD. Others and we have noted that the E1A-D24 mutation confers a minor defective phenotype when non-quiescent or non-epithelial cells are used. [38] [39] [40] In consequence, this pRB-binding domain mutation has been combined with the E2F-control of viral gene expression to reduce viral replication and late viral gene expression in nonproliferating cells.
14 In a further development of this strategy a poly-A signal has been used to insulate the E2F-1 promoter. 15 This insulation strategy was also used when the E1A-D24 mutation was combined with the tyrosinase promoter. 6 Our results with ICOVIR-1 also indicate that such an insulation decreases cryptic transcription of E1A from the left end of Ad genome in normal cells and it can contribute to improve the promoter fidelity. However, transcription termination cannot completely insulate the E1a promoter. Our results using the DM-1 insulator confirm that insulation based on CTCF binding allows a tighter control of the promoter with respect to the presence of only the poly-A signal. 28 Despite that the issue of whether insulation requires a chromosomal-like context is still controversial and this has questioned its function in an adenovirus genome, our results confirm the function of CTCF enhancer blocking in adenovirus. This function has been related to the ability of the virus genome to form nucleosomes with cellular histones. 27 The observed increase in virus selectivity in vitro also resulted in a decrease of in vivo toxicity upon systemic administration of ICOVIR-2. The mouse is a semipermissive species for human Ad5 replication 41 and a complete profile of adenoviral toxicity cannot be obtained with this model. However, early adenoviral gene expression occurs normally in rodent cells and causes an important part of the adenovirus-induced hepatotoxicity. In consequence, a number of studies have characterized the in vivo toxicity of conditionally replicating vectors after intravenous administration in mice. 14, 42, 43 Our results show that Ad-D24RGD increased transaminase levels to the same extent as AdwtRGD and this resulted in an important loss of animal body weight. In contrast, systemic administration of ICOVIR-1 and ICOVIR-2 produced much lower expression of E1A in the liver and transaminase raise. Interestingly, E1A expression in the liver of ICOVIR-2-treated mice was lower than with in those treated with ICOVIR-1. Despite no significant differences were detected in transaminase levels, body weight variations also indicated a reduced toxicity of ICOVIR-2 when compared to ICOVIR-1. These data confirm the fidelity of the DM-1/E2F-driven expression of E1A in vivo. Moreover, the reduced toxicity of ICOVIR-2 may allow increasing the dose that can be systemically injected.
The potency of ICOVIR-1 and ICOVIR-2 is generally maintained with respect to AdwtRGD when assayed on tumor cell lines. Western blot analysis revealed a wildtype level of E1A expression after infection with both mutants in some tumor cell lines, whereas this level was slightly reduced in others. We did not detect a reduced level of E2F-1 protein by Western blot in those cell lines where E1A protein level was reduced (data not shown). This lack of correlation between E2F-1 and E1A protein levels could be explained by the complexity of E2F-based transcriptional regulation (activator, inhibitor and repressor complexes). In this sense, E2F-1-binding sites in virus genomes are more prone to be regulated by activation with free E2F, whereas endogenous promoters Insulated E2F promoter for RB-dependent oncolysis M Majem et al rely more on repression by E2F-Rb-histone deacetylase complexes that depend on chromatin structure. Progeny production and cytotoxicity analysis also demonstrated similar levels of replication in some tumor cell lines but decreased levels in others. This loss of potency in certain tumor cell lines is a limitation that has been described for other E2F-regulated oncolytic adenoviruses [14] [15] [16] and it is independent of the presence of the DM-1 insulator since we have found it both in ICOVIR-1 and in ICOVIR-2. Therefore, our data suggests that it is important to achieve a near wild-type level of E1A expression to maintain efficient virus replication, contrary to some reports on wide variations of E1A with little effects on replication. 6, 44 Several strategies can be envisaged to address this limitation. The loss of potency of ICOVIR-2 in some tumor cells could be increased to the level of E1A translation using kozak sequences, which facilitates the initial binding of the E1A mRNA to the small subunit of the ribosome. 45 Moreover, the addition of E2F-Sp1-binding sites could improve the strength of the E2F-1 promoter. On the other hand, E1A expression through the viral cycle is finely tuned. It can be hypothesized that a promoter with a constitutive activity such as E2F-1 could not yield optimal E1A levels during the virus late phase. In this regard, prolonged expression of E1A and E1A-dependent viral and cellular genes has been suggested to interfere with the activation of the adenovirus major late promoter and consequently could affect viral replication. 46 To avoid this problem inhibition of E1a expression with RNAi under a late phase promoter such as the VA-RNA promoter could be considered. These strategies could be combined with others aimed to increase the lytic potency of oncolytic viruses, such as the expression of cytotoxic or apoptosisinducing genes. These modifications may be specially relevant to obtain antitumoral efficacy upon systemic delivery.
The antitumoral potency in vivo of ICOVIR-2 was equivalent to that of AdwtRGD when administered intratumorally for 3 consecutive days in a subcutaneous pancreatic model. Tumor growth was inhibited as a consequence of virus replication within the tumor mass. The addition of the RGD motif in the HI loop of the adenovirus fiber has demonstrated to enhance the in vivo oncolytic potency of different conditionally replicative adenovirus, including Ad-D24. 31 ,47,48 RGD-modified viruses are able to overcome the inefficient infection into cells lacking the primary adenovirus receptor (CAR), such as many tumor cells without increasing hepatotoxicity. 47 ICOVIR-2 includes the RGD modification in addition to its selectivity mechanisms which enhances the spreading of the virus within the tumor masses. Insulated E2F promoter for RB-dependent oncolysis M Majem et al
Taken together, our results indicate that the incorporation of an insulated form of the E2F-1 promoter to the Ad-D24RGD background allows ICOVIR-2 to display a better selectivity for cells with a deregulated E2F/RB pathway while preserving a potent antitumoral activity. The in vivo reduced hepatotoxicity improves the therapeutic index of this oncolytic adenovirus. Since the presence of alterations in the RB pathway is a characteristic shared by practically all human cancers, 20 ICOVIR-2 may be valuable for the treatment of a broad range of tumors. 
